In a dramatic new chapter in the new Cold War competition between the US and China, the Food and Drug Administration (FDA) has announced that it is blocking a new lung cancer drug from the US market. Ivonescimab was set up to overtake Merck's Keytruda as the world's best-selling oncology drug, but the FDA announced it would not allow the drug access to the highly lucrative US market. The stated reason was that while the drug performed well in tests of Asian patients, it had not been sufficiently tested in Westerners. In fact, 35% of the participants in the experiments are from Western countries (including the United States itself). The decision is the latest attempt by the US to block China's rise as a technological power. In the past, Washington has banned Huawei technology, blocked high-end Chinese electric vehicles, and barred Chinese drones and social media apps from offshore. The decision to stop ivonescimab from being used, however, is literally a life and death decision, and will lead to countless Americans dying of cancer.